PCM
AVTX icon

Prelude Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Prelude Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$524K Buy
+35,096
New +$549K 0.04% 485
2025
Q4 		– Sell
-24,628
Closed -$313K – 1298
2025
Q3 		$313K Buy
+24,628
New +$212K 0.02% 713
2020
Q3 		– Hold
0
– – – 1812
2020
Q2 		– Hold
0
– – – 1943

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Prelude Capital Management's AVTX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 35,096 shares worth $524K. The stake represents 0.04% of the portfolio and ranks #485 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in AVTX as recently as Q3 2025.

Prelude Capital Management first reported a position in AVTX in Q3 2025 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Prelude Capital Management held 35,096 shares of Avalo Therapeutics worth $524K as of Q1 2026.
  • Avalo Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Avalo Therapeutics made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #485 holding.
  • Prelude Capital Management first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.